Jaguar Health Inc. (JAGX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Jaguar Health Inc. (NASDAQ: JAGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.62 (-20.59% 1D, market cap $12.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, JAGX ranks #872 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JAGX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 67.2%, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and BOLT (Bolt Biotherapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, JAGX leads on earnings multiple (N/A) while JAGX leads on capital efficiency (-35.0% ROIC).
Per JAGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585608), Jaguar Health Inc. generated $11.5M in revenue (-1.5% YoY), -$54.0K in net income, and -$23.7M in free cash flow against $38.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 40.2 (NEUTRAL RANGE)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While JAGX currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.00) and Max Pain ($1.70) forces dealer call-delta covering toward $1,157.63.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Jaguar Health Inc. (JAGX) dropped -20.59% to $1.62, trading at 2% of its 52-week range ($1.6 – $1102.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
ACCESS Newswire report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
Premarket movers for Nov. 2, 2026: CLRO and EVGO led gainers while KPTI and DRUG led decliners ahead of the US open.
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on JAGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for JAGX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Jaguar Health Inc. (JAGX) ranks #872 by composite RQD confidence (28/100, grade E) and #870 by equity capitalization ($12.6M). Within this direct 5-issuer industry benchmark cohort, JAGX leads on earnings valuation at N/A trailing P/E, while JAGX leads on capital efficiency and profitability with -35.0% ROIC and 67.2% gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with JAGX at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| JAGX
ACTIVE
Jaguar Health Inc. | E | 28/100 | — | 67.2% | -35.0% | -20.59% | $12.6M | Benchmark Subject |
| HIND Vyome Holdings Inc. | E | 29/100 | — | 68.4% | -35.0% | +2.86% | $12.6M | /hind-vs-jagx → |
| BOLT Bolt Biotherapeutics Inc. | D- | 37/100 | — | — | -35.0% | +3.62% | $12.7M | /bolt-vs-jagx → |
| BIVI BioVie Inc. (Class A) | E | 32/100 | — | — | -35.0% | +3.62% | $12.4M | /bivi-vs-jagx → |
| KTTA Pasithea Therapeutics Corp. | D- | 40/100 | — | — | -35.0% | +0.16% | $12.4M | /ktta-vs-jagx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jaguar Health Inc. (JAGX) reported GAAP revenue of $11.5M (-1.5% vs. FY2024 revenue of $11.7M , and +17.9% cumulative change since FY2023) , GAAP net income of -$54.0K, operating cash flow of -$23.7M, and free cash flow of -$23.7M (+19.4% YoY). On the balance sheet, JAGX closed FY2025 with $38.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $11.5M | -$54.0K | -$23.7M | -$23.7M | $38.3M | — |
| FY2024 (FY) | 2024-12-31 | $11.7M | -$39.3K | -$29.4M | -$29.4M | $53.4M | — |
| FY2023 (FY) | 2023-12-31 | $9.8M | -$41.9K | -$33.2M | -$33.2M | — | — |
As of 2026-11-03, Jaguar Health Inc. (NASDAQ: JAGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.62 (-20.59% 1D, market cap $12.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, JAGX ranks #872 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JAGX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 67.2%, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and BOLT (Bolt Biotherapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, JAGX leads on earnings multiple (N/A) while JAGX leads on capital efficiency (-35.0% ROIC).
Per JAGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585608), Jaguar Health Inc. generated $11.5M in revenue (-1.5% YoY), -$54.0K in net income, and -$23.7M in free cash flow against $38.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
JAGX last traded at $1.62 (-20.59% on volume of 383,580 shares), positioning the stock -73.00% below its 50-day simple moving average ($6.00) and -98.58% below its 200-day simple moving average ($114.36). Across its 52-week range of $1.60 to $1,102.50, JAGX sits at the 0.0% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.42 to $1.82).
Why JAGX Stock dropped -20.59% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, JAGX scores 28 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). Every pillar sits in the low range, and the two weakest, cash engine and institutional/insider flow, are the ones that most directly determine whether a company can self-fund and whether informed capital is backing it. For a prospective investor, the rating's implication is that the reported economics do not currently generate cash, the balance-sheet signals are weak, and there is little evidence of concentrated conviction from institutions or insiders. Any upside case would have to rest on factors outside the cash engine, such as a catalyst that changes the funding picture, and the source data does not establish one. The rating frames the stock as a high-risk, low-conviction situation rather than a value opportunity.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $11.5M | $-45.9M | $-0.1M | N/A | $-23.7M | $1.0M | N/A |
| FY 2024 | $11.7M | $-30.8M | $-0.0M | N/A | $-29.4M | $8.0M | N/A |
| FY 2023 | $9.8M | $-34.3M | $-0.0M | N/A | $-33.2M | N/A | N/A |
Per the SEC financials and market data, operating margin is -60% and net margin is -0.5% against a gross margin of 67.2%, indicating that the gap between gross profit and operating results is driven by operating costs rather than product-level economics. ROIC is -35%. The forensic metrics per the Roarable RQD rating are an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and Debt/Equity of 0.5. Reported cash declined from $8.0M to $1.0M over FY 2024 to FY 2025 while free cash flow remained negative in each reported year.
Per the recent news and catalysts feed, the most recent item (flagged YELLOW, market wire) concerns a targeted mid-2027 MVID NDA filing as the crofelemer intestinal failure program advances. A second YELLOW item reports a declared special stock dividend of Series R Convertible Preferred Shares, followed by a GREEN-flagged catalyst item on setting a record date for that special dividend, and an ACCESS Newswire update on the same special dividend. Other items include a StockInvest.us forecast piece, a Moomoo analyst-ratings piece, and a YELLOW market-wire item. Watch items are the timing of the MVID filing relative to the cash position reported in the financials, and the preferred share distribution, which is a structural event affecting the capital stack. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are recorded.
Real-time company headlines, analyst actions, and sector developments for Jaguar Health Inc. (JAGX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
ACCESS Newswire report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.
Welcome to the JAGX (Jaguar Health Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on JAGX, but look at what you are paying: current EV/EBITDA multiples with 67.2% gross margins. Unless Jaguar Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on JAGX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.04 (52-wk range $1.60 - $1102.50), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).